{"id":995124,"date":"2026-08-13T16:16:52","date_gmt":"2026-08-13T20:16:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights\/"},"modified":"2026-08-13T16:16:52","modified_gmt":"2026-08-13T20:16:52","slug":"fortress-biotech-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights\/","title":{"rendered":"Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights"},"content":{"rendered":"
\n

\n Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025<\/em>\n <\/p>\n

\n Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO<\/em>
\n \u00ae<\/sup>
\n and UNLOXCYT<\/em>
\n \u2122<\/em>\n <\/p>\n

MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (\u201cFortress\u201d), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2026.<\/p>\n

Lindsay A. Rosenwald, M.D., Fortress\u2019 Chairman, President and Chief Executive Officer, said, \u201cThe second quarter of 2026 reflected continued momentum across our portfolio and further progress in unlocking long-term shareholder value. Our subsidiary Urica Therapeutics, Inc.\u2019s (\u201cUrica\u201d) equity position in Crystalys Therapeutics, Inc. (\u201cCrystalys\u201d) was strengthened by Crystalys’ $130 million Series B financing, which will support the late-stage global development and commercialization preparation for dotinurad, a next-generation oral URAT1 inhibitor for gout, on which Urica is entitled to a 3% royalty on future net sales. Journey Medical also continues to scale Emrosi\u00ae<\/sup>, securing a third major GPO contract that expanded payer access to over 150 million commercial lives. Coming off the momentum of ZYCUBO\u00ae<\/sup>‘s approval and the $205 million PRV sale in the first quarter, we enter the second half of 2026 with a favorable cash balance that positions us to continue executing on our pipeline and business development priorities.\u201d<\/p>\n

Dr. Rosenwald added, \u201cWe continued to see encouraging clinical progress this quarter on our partnered programs. AstraZeneca reported additional prespecified subgroup analyses for anselamimab (formerly CAEL-101) showing a 62% improvement in survival and a 71% reduction in cardiovascular hospitalizations among kappa predominant light chain isotype patients in the CARES program, and indicated that it plans to submit these findings to regulatory authorities. Crystalys also continues to advance dotinurad’s two global Phase 3 trials while initiating a new Phase 2 study in difficult-to-treat gout, broadening the program’s potential patient population. With a diversified portfolio spanning commercial, late-stage, and development-stage programs, including royalties, milestones and equity, and a strengthened balance sheet following the ZYCUBO\u00ae<\/sup> PRV monetization, we believe Fortress is well positioned to advance strategic initiatives and drive long-term value for our shareholders.\u201d<\/p>\n

\n
\n Recent Corporate Highlights<\/u>
\n <\/strong>
\n
\n
\n 1<\/u>
\n <\/strong>
\n <\/sup>
\n
\n :<\/u>
\n <\/strong>\n <\/p>\n

\n Commercial Portfolio Updates<\/em>\n <\/p>\n